

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: IFT2/18 - Immunophenotypisation

Dead line: 22.10.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(253) CD 3+ T lymphocytes					99						99	92	93%	
Samples and groups	[%]													
Sample A		65,4	2,3	3,5	99	CVP	65,4	0,56	7%	60,8	70	99	95	96%
(12) Beckman Coulter		65,6	1,9	2,8	49	0						49		
(88) Becton Dickinson		64,7	2,5	3,8	29	0						29		
(177) MINDRAY		64,9	2,8	4,3	7	0						7		
(190) Exbio Praha		67,6	3,0	4,4	7	0						7		
Other					7	0						7		
							1x 0, 1x 28, 4x 36, 1x 999							
Sample B		68,3	1,6	2,4	99	CVP	68,3	0,40	7%	63,5	73,1	99	95	96%
(12) Beckman Coulter		68,8	1,2	1,8	49	0						49		
(88) Becton Dickinson		67,3	2,0	2,9	29	0						29		
(177) MINDRAY		67,8	1,1	1,7	7	0						7		
(190) Exbio Praha		68,5	2,6	3,7	7	0						7		
Other					7	0						7		
							1x 0, 1x 28, 4x 36, 1x 999							
(254) CD 4+ T lymphocytes					99						99	93	94%	
Samples and groups	[%]													
Sample A		44,4	2,3	5,1	99	CVP	44,4	0,56	10%	39,9	48,9	99	94	95%
(12) Beckman Coulter		44,7	2,0	4,5	50	0						50		
(36) Immunotech		45,2	1,7	3,8	5	0						5		
(88) Becton Dickinson		43,9	2,4	5,5	30	0						30		
(177) MINDRAY		44,6	2,4	5,4	7	0						7		
(190) Exbio Praha		45,8	3,3	7,1	5	0						5		
Other					2	0						2		
							2x 999							
Sample B		52,4	1,5	2,8	99	CVP	52,4	0,36	10%	47,1	57,7	99	96	97%
(12) Beckman Coulter		52,8	1,1	2,1	50	0						50		
(36) Immunotech		53,5	1,3	2,5	5	0						5		
(88) Becton Dickinson		51,7	1,9	3,6	30	0						30		
(177) MINDRAY		51,8	1,5	2,9	7	0						7		
(190) Exbio Praha		52,7	0,96	1,8	5	0						5		
Other					2	0						2		
							2x 999							
(255) CD 8+ T lymphocytes					99						99	92	93%	
Samples and groups	[%]													
Sample A		16,0	1,1	7,0	99	CVP	16	0,28	17%	13,2	18,8	99	95	96%
(12) Beckman Coulter		15,5	1,0	6,6	50	0						50		
(36) Immunotech		16,2	1,2	7,4	5	0						5		
(88) Becton Dickinson		16,5	0,99	6,0	28	0						28		
(177) MINDRAY		16,5	0,74	4,5	7	0						7		
(190) Exbio Praha		16,8	0,56	3,3	6	0						6		
Other					3	0						3		
							1x 28, 2x 999							
Sample B		13,4	0,75	5,6	99	CVP	13,4	0,19	17%	11,1	15,7	99	94	95%
(12) Beckman Coulter		13,2	0,77	5,8	50	0						50		
(36) Immunotech		14,2	1,2	8,6	5	0						5		
(88) Becton Dickinson		13,4	0,72	5,4	28	0						28		
(177) MINDRAY		13,6	0,89	6,5	7	0						7		
(190) Exbio Praha		13,6	0,37	2,7	6	0						6		
Other					3	0						3		
							1x 28, 2x 999							
(256) B lymphocytes					99						99	97	98%	
Samples and groups	[%]													
Sample A		17,6	1,2	7,0	99	CVP	17,6	0,31	30%	12,3	22,9	99	99	100%
(12) Beckman Coulter		17,3	1,2	6,9	53	0						53		
(36) Immunotech		17,8	2,0	11	6	0						6		
(88) Becton Dickinson		17,8	1,2	6,7	24	0						24		
(177) MINDRAY		18,4	2,1	12	7	0						7		
(190) Exbio Praha		18,4	1,0	5,5	8	0						8		
Other					1	0						1		
							1x 999							
Sample B		13,5	0,85	6,3	99	CVP	13,5	0,21	30%	9,45	17,6	99	97	98%
(12) Beckman Coulter		13,4	0,86	6,4	53	0						53		
(36) Immunotech		12,4	1,6	13	6	0						6		
(88) Becton Dickinson		13,7	0,81	5,9	24	0						24		
(177) MINDRAY		14,2	1,2	8,4	7	0						7		

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: IFT2/18 - Immunophenotypisation

Dead line: 22.10.2018

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}										
							AV	U _{AV}	D _{max}	LL	UL														
(256) B lymphocytes													99	99	97	98%									
Samples and groups													[%]												
Sample B													99	97	98%										
(190) Exbio Praha													13,5	0,85	6,3	99	CVP	13,5	0,21	30%	9,45	17,6	99	97	98%
Other													14,4	1,4	9,4	8	0						8		
																1	0						1		
																		1x 999							
(257) NK cells													99	99	91	92%									
Samples and groups													[%]												
Sample A													14,5	1,8	13	99	CVP	14,5	0,45	26%	10,7	18,3	99	95	96%
(12) Beckman Coulter													14,5	1,7	12	50	0						50		
(36) Immunotech													13,3	1,9	14	6	0						6		
(88) Becton Dickinson													14,9	1,9	12	29	0						29		
(177) MINDRAY													14,6	0,68	4,7	7	0						7		
(190) Exbio Praha													13,2	1,7	13	6	0						6		
Other																1	0						1		
																		1x 999							
Sample B													16,3	1,6	9,5	99	CVP	16,3	0,38	26%	12	20,6	99	92	93%
(12) Beckman Coulter													16,1	1,3	7,9	50	0						50		
(36) Immunotech													15,1	0,074	0,49	6	1						6		
(88) Becton Dickinson													17,3	1,9	11	29	0						29		
(177) MINDRAY													17,2	1,2	6,8	7	0						7		
(190) Exbio Praha													15,1	0,95	6,3	6	0						6		
Other																1	0						1		
																		1x 999							

st_kn_p

End of report

Printed: 01.11.2018